Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients

Liver Transplantation

Volumn 19, Issue 4, 2013, Pages 463-465

  O'Leary, Jacqueline G ^a   McKenna, Gregory J ^a   Klintmalm, Göran B ^a   Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA; PEGYLATED INTERFERON ALPHA 2A; RAPAMYCIN; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL ARTICLE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LETTER; LIVER TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; SIROLIMUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84875736748     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23623     Document Type: Letter

References (7)

1. Terrault NA, Berenguer M,. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,; for American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
3. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
4. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630.
5. McKenna GJ, Ruiz R, Onaca N, Campsen J, Klintmalm E, Levy MF, et al. The impact of timing in sirolimus conversion for renal insufficiency in liver transplant recipients [abstract]. Liver Transpl 2011; 17 (suppl 1): A84.
6. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468.e1.
7. Coilly A, Roche B, Dumortier J, Botta-Fridlund D, Leroy V, Pageaux PG, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. Hepatology 2012; 56 (suppl 1): 194A.